The UK draft NICE guideline on depression in adults was sent out for stakeholder consultation between July and September 2017. The final guideline publication date currently remains 'to be confirmed'. This paper sets out key concerns with the methodology employed in the guideline and its impact on recommendations for psychodynamic psychotherapies for complex and persistent depression. The draft largely ignored the subjective experiences and voices of service users, carers and members of the public, using out of date limited evidence of service user and carer experiences. The guideline fails to incorporate what limited qualitative evidence it reviewed into any treatment recommendations. The Guideline Committee created its own method for categorising depression by longevity, severity and complexity. This has resulted in erroneous and unhelpful classifications of research studies under groupings which do not match clinical and service user experiences or US and European approaches, rendering analyses and conclusions unreliable. We also outline instances of incorrect classification of psychodynamic treatments (such as inclusion of non bona-fide treatments or exclusion of relevant bona-fide treatment studies) which enables the omission of a recommendation for psychodynamic psychotherapy for complex and persistent depression. Depression is often a long-term condition or can become so if immediate care is inadequate; yet the draft recommendations are all made on the basis of short-term outcome data (with often less than 8 weeks between baseline and outcome). NICE guidelines for longterm physical conditions would treat this evidence as inadequate. Finally, the draft guideline used the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) system of assessing methodological quality in such a way as to produce a systematic bias in favour of drug trials, selectively omitting trial data with long-term follow up points and those which used non-symptom outcomes. Herein we consider the increasingly evident limitations of the paradigm NICE works within for ensuring patient choice and equity of access to a wide range of therapies.
Published in Psychoanalytic Psychotherapy online 9 April 2018 https://www.tandfonline.com/eprint/awkDyW7UQ5bUrvHABPnn/full 8 and chronicity and how these impact on their handling of psychodynamic psychotherapy RCTs. We also illustrate how the incorrect categorisation of psychodynamic psychotherapies leads to selective exclusion of bona-fide treatments and selective inclusion of non bona-fide treatments, all of which leads to unreliable analyses and conclusions.
An idiosyncratic approach to depression severity
The draft guidelines used a method of dividing trial populations by dichotomising baseline severity as 'more severe' or 'less severe'. This single reductive proxy estimate of severity depends on the un-evidenced assumption that the equivalence algorithm combining different depression rating scales developed by the GC is reliable and valid. Most of the component measures taken account of have their own range of severity categories, validated in the literature. The decision to ignore these risks misrepresenting the true severity of a study population and thus forming inaccurate judgments on the effectiveness of treatments. For instance, the study populations in the Fonagy et al (2015) and Town et al (2017) RCTs of LTPP and STPP respectively are both categorised as 'Less severe' for baseline severity.
Fonagy et al (2015) and Town et al (2017) used the 17-item Hamilton Depression rating scale (HAMD) and according to the HAMD validated categories, the mean baseline scores for both studies fell in the 'severe' range. This indicates a significant discrepancy between the guideline method and the method established in the literature.
The GC approach to severity also fails to take account of individual change and amount of change. It is more difficult for a treatment to move an individual from a very high score on a measure to the target low score which would count as 'full remission'. It is easier to move someone into full remission if they start on or closer to the low score one has to reach to count as being in remission. It would therefore have been important for the guideline to look at rates of partial remission as well as full remission, particularly where participants begin the intervention with severe depression.
It would be yet more useful to look at individual change. HSCIC, 2016) . IAPT reports then examine 'reliable improvement' (which considers baseline and end-point severity, rather than only whether the case met 'clinical caseness' at either point). This finds that 62.2% of IAPT clients improve -a higher figure than when just reporting % reaching the 'recovery' point. Using 'reliable improvement' methods in the trials included in the guideline meta-analyses would offer a fuller picture; which is particularly important when trials have studied the treatment of markedly severe and refractory populations for whom currently there are few well-evidenced treatments available.
Chronicity: mistaken augmentation strategies
The draft guideline separates RCTs of CD and TRD into two discrete categories, whether or not study populations fell into both categories. RCTs that fit both categories were allocated to one category or the other with no explicit criterion for deciding which category (Table 120) While the participants in the LTPP study are described by the authors as 'treatment resistant', participants do not meet the criteria for TRD defined by NICE and the intervention was not an 'augmentation strategy'. The criteria were broadly inclusive, stating participants should have had an 'Inadequate response to least two different treatments (mean of 3.7 previously failed treatment attempts) ' (Fonagy et al, 2015) . This represents a fundamentally different approach to 'resistance'. There was no requirement in the inclusion criteria that the medication received need be recent or current. Although the appendices of the guideline indicate that the study met criteria for CD as well as TRD, it is analysed along with other TRD studies. It is similarly misleading to classify Town et al (2017) as an augmentation strategy, particularly given that two thirds in the STPP group reduced or came off medication
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Selective inclusion of non bona-fide treatments
The recent RCT by Town et al (2017) Participants had high levels of childhood adversity (89% -unpublished data available on request); and high comorbidity: 47% had musculoskeletal problems, 25% had gastrointestinal problems; 91% had at least one other comorbid Axis 1 disorder; 54% were unemployed; the mean baseline Global Assessment of Functioning (GAF) score was 49.1; 45% had made at least one previous suicide attempt etc. Clinically this is a very complex population, as was the Town et al (2017) sample, yet these trials are classed as TRD only -rather than chronic and/or complex, highlighting the systematic ignoring of individual subjectivities which in many cases are likely to be highly predicated on childhood adversity and trauma.
Five RCTs of STPP were excluded on the grounds that these studies included ( study of Behaviour Therapy) had failed to administer a formal PD assessment and precise numbers on those with an unconfirmed PD diagnosis were not provided. Hence only a 'best guess' could speculate how many participants in this small trial (N=24) may have had PD.
The GC conclude that the evidence base for complex depression is limited in volume having only included five small RCTs. If bona-fide studies of therapies are selectively excluded from data analytic approaches to examine the effects of a specific treatment in this way, estimates of within-and between-group differences can be expected to be unreliable and ensuing quality statements and recommendations questionable (Leichsenring et al, 2017) . Likewise, including non bona-fide interventions as noted previously in the inclusion of BSP as an STPP, has an equally problematic impact on guideline recommendations.
We acknowledge that some of these technical issues around categorising trials by chronicity, severity and complexity may appear akin to dancing on a pin head and that perhaps a redrawing of the boundaries would likely open yet new potholes. Yet this in itself illustrates that the scientific methods employed by NICE ultimately rely on a series of multiple complex decisions made by a relatively small group of appointed experts forced to come to a consensus to drive through the guideline development process. There are limited objective facts guiding these decisions and there are so many decisions to be made at each stage of review that there are multiple opportunities for bias and/or error to occur.
Cumulatively, the result of these decisions for the proposed guideline update is the continued omission of an appropriate and specific place for the implementation of psychodynamic 
Parity with other Long-Term Conditions?
The draft guideline states that "the aim of intervention is to restore health through the relief of symptoms and restoration of function, and in the longer term, to prevent relapse" (p.40, l.31-32) . It furthermore highlights the high likelihood of relapse or deterioration in patients with depression described under the heading of 'treatment resistance' (section 8.1.2).
In spite of this, the draft guideline does not take account of long-term follow-up. Indeed, it excluded long-term follow-up data that might demonstrate whether the aims of interventions have indeed been achieved.
The choice to omit long-term data is particularly difficult to comprehend in the sections dealing with TRD and CD and is likely due to most trials not collecting or reporting follow-up data. This is, however, not an adequate justification. Calls for RCTs of interventions for depression to include longer term follow-up years after the end of treatment,
given the episodic nature of depression, have been made repeatedly (e.g. McPherson et al, 2005; Goodyer et al, 2008; Goodyer et al, 2011; Goodyer et al, 2017) . According to criteria adopted by NICE as well as the APA and EPA, chronic forms of depression must last for at least two years. Studies included in the NICE review report mean durations of illness as long as 7.8 years (Keller et al, 2000) ; 7.6 years (Kocsis et al, 2009); and 24.4 years (Fonagy et al, 2015) . Given the actual mean duration of illness observed, there is an even stronger case for looking at data from follow-up periods in more chronic forms of depression. Moreover, Published in Psychoanalytic Psychotherapy online 9 April 2018 https://www.tandfonline.com/eprint/awkDyW7UQ5bUrvHABPnn/full 15
